Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation  

作　　者：Konstantinos Ouranos Anthi Chatziioannou Ioannis Goulis Emmanouil Sinakos 

机构地区：[1]4th Medical Department,Hippokratio Hospital,Aristotle University of Thessaloniki,Thessaloniki 54642,Greece

出　　处：《World Journal of Transplantation》2022年第11期331-346,共16页世界移植杂志

摘　　要：Hepatocellular carcinoma(HCC)is an aggressive primary liver neoplasm that,according to tumor stage,can be treated with resection,transplantation,locoregional treatment options,or systemic therapy.Although interventions only in early-stage disease can offer complete tumor regression,systemic therapy in advanced disease can significantly prolong overall survival,according to published clinical trials.The emergence of immunotherapy in the field of cancer therapy has had a positive impact on patients with HCC,resulting in atezolizumab–bevacizumab currently being the first-line option for treatment of advanced HCC.In light of this,application of immunotherapy in the preoperative process could increase the number of patients fulfilling the criteria for liver transplantation(LT).Implementation of this approach is faced with challenges regarding the safety of immunotherapy and the possibly increased risk of rejection in the perioperative period.Case reports and clinical trials assessing the safety profile and effectiveness of neoadjuvant immunotherapy,highlight important aspects regarding this newly evolving approach to HCC management.More studies need to be conducted in order to reach a consensus regarding the optimal way to administer immunotherapy prior to LT.In this review,we summarize the role,safety profile and future considerations regarding the use of neoadjuvant immunotherapy prior to LT in patients with HCC.

关 键 词：Hepatocellular carcinoma IMMUNOTHERAPY Tumor downsizing Liver transplantation NEOADJUVANT REJECTION 

分 类 号：R73[医药卫生—肿瘤]